UCSF Study Finds Dopamine Pathway Explains Why Humans Learn to Like Bitter Coffee

Dopamine Pathway Explains Flavor Preferences

A newly identified dopamine pathway linking the gut to the brain explains why humans learn to enjoy initially unpleasant flavors, such as black coffee.

Research published November 4 in Nature reveals that this “slow” signaling system operates differently than the rapid dopamine responses triggered by the sight or smell of food.

While rapid dopamine signals help the brain recognize immediate rewards, this slower process responds to nutrients detected in the digestive tract.

According to a study from the University of California, San Francisco (UCSF), this pathway allows the brain to learn the nutritional value of food after it has been consumed.

Learning Through Gut-Brain Communication

To isolate the effects of nutrients from the experience of taste, researchers delivered sugar water or a milkshake-like liquid directly into the stomachs of mice. This method allowed them to observe how the body communicates with the brain without the interference of taste buds.

The team found that nutrients triggered a prolonged dopamine response in the basolateral amygdala (BLA).

“We’ve shown that this slow dopamine system is what drives us to learn to like certain foods over time, and we can see where and how that happens,” said Zachary Knight, PhD, a professor of physiology at UCSF and senior author of the study.

Once the brain associates the bitterness of coffee with the stimulating effects of caffeine, the flavor itself becomes more rewarding. When researchers blocked this pathway in mice, the animals lost the ability to associate unfamiliar flavors with calories, even though their eating habits remained unchanged.

UCSF Study Finds Dopamine Pathway Explains Why Humans Learn to Like Bitter Coffee
Photo: Yahoo Health

Left-Brain Nutrient Response

The research team observed an unexpected asymmetry in how the brain processes these nutrient signals. Both mouse experiments and human imaging studies indicated that the dopamine response was significantly more concentrated in the left side of the BLA.

Brain imaging involving 13 men revealed nutrient-related activity concentrated on the left side of the same brain region.

A separate functional magnetic resonance imaging (fMRI) study of 38 adults, led by Marc Tittgemeyer, PhD, observed similar activity patterns after the consumption of glucose.

Knight noted that this imbalance was surprising, as brain networks responsible for essential functions like feeding are typically expected to be symmetrical.

Potential for Future Appetite Treatments

The discovery of this pathway suggests it could be used to influence human food cravings. While the study did not test GLP-1 medications, Knight suggested that these drugs might potentially reduce the dopamine signals generated by nutrients in the digestive system.

If this hypothesis is confirmed, future treatments could theoretically target the brain’s ability to learn food preferences rather than simply suppressing appetite. By fine-tuning the communication between the gut and the brain, researchers hope to understand how to shift preferences for specific food types.

***

Common Questions About Flavor Learning

Why do we learn to like bitter foods like coffee?
The brain associates the flavor of coffee with the stimulating effects of caffeine. This slow dopamine pathway reinforces that connection after the caffeine is consumed, making the previously unpleasant taste become rewarding over time.

Does this dopamine system work the same way in humans and mice?
Yes, both species demonstrate a similar, prolonged dopamine response in the basolateral amygdala.

In both cases, the response is notably stronger in the left side of the brain, a finding that surprised the research team.

Can this discovery immediately stop food cravings?
No, the findings do not currently offer a way to eliminate cravings. The research maps a fundamental biological process, but further study is needed to determine if this pathway can be safely and effectively targeted by future medical treatments.